Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Reddy's Laboratories ( Obeda ), Zydus Lifesciences ( Alterme , Mashema and Semaglyn ), Torrent Pharmaceuticals ( Sembolic and Semalix ), Alkem Laboratories ( Semasize , Obesema and Hepaglide ), Glenmark Pharmaceuticals ( Glipiq ) and Eris Lifesciences ( Sundae )
Dosage increases are usually spaced about every four weeks
The published research has not settled this
Research shows that it enhances emotional well-being, helping you feel more positive and focused throughout the day
zeta potential 51.3 mV) are not considered optimal for BBB permeability according to current nanoneuroscience literature (Hong et al
Our Oral GLP-1 Programme Proprietary delivery technology microencapsulates peptides for oral delivery to a specific area of the gut, using pH sensitive release mechanism to deliver the drug to its intended site of action Potential to overcome oral delivery challenges of peptide-based biologicals Effectiveness of the technology has already been validated via the commercialisation of encapsulated oral probiotics and nutraceuticals by AnaBio Technologies, our collaborative partner Proof of Concept Trial Proof of Concept Trial Progressing towards proof of concept trial to determine that a GLP-1R agonist can be successfully delivered orally in humans expected to commence H2 2026, with the potential for partnering on positive data
